KURA ONCOLOGY, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
KURA ONCOLOGY, INC. (KURA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $8.21 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- KURA ONCOLOGY, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $8.21M, a 18.13% increase year-over-year.
- KURA ONCOLOGY, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $8.42M, a 7.32% increase year-over-year.
- KURA ONCOLOGY, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $10.96M, a 31.73% increase year-over-year.
- KURA ONCOLOGY, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $6.95M, a 17.57% decline year-over-year.
- KURA ONCOLOGY, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $37.11M, a 9.47% increase from fiscal 2024.
- KURA ONCOLOGY, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $33.90M, a 20.71% increase from fiscal 2023.
- KURA ONCOLOGY, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $28.08M, a 6.70% increase from fiscal 2022.
- KURA ONCOLOGY, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $26.32M, a 11.62% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 4 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $8.21M 10-Q · filed 2026-08-12 | $16.63M derived: sum of 2 quarters · filed 2026-08-12 | |||
| 2026-03-31 | $8.42M 10-Q · filed 2026-08-12 | ||||
| 2025-12-31 | $37.11M 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | $10.96M 10-Q · filed 2025-11-04 | $17.91M derived: sum of 2 quarters · filed 2026-08-12 | $25.76M derived: sum of 3 quarters · filed 2026-08-12 | ||
| 2025-06-30 | $6.95M 10-Q · filed 2026-08-12 | $14.79M derived: sum of 2 quarters · filed 2026-08-12 | |||
| 2025-03-31 | $7.84M 10-Q · filed 2026-08-12 | ||||
| 2024-12-31 | $33.90M 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | $8.32M 10-Q · filed 2025-11-04 | $16.75M derived: sum of 2 quarters · filed 2025-11-04 | $25.27M derived: sum of 3 quarters · filed 2025-11-04 | ||
| 2024-06-30 | $8.43M 10-Q · filed 2025-11-04 | $16.94M derived: sum of 2 quarters · filed 2025-11-04 | |||
| 2024-03-31 | $8.51M 10-Q · filed 2025-11-04 | ||||
| 2023-12-31 | $28.08M 10-K · filed 2026-03-05 | ||||
| 2023-09-30 | $7.09M 10-Q · filed 2024-11-07 | $14.08M derived: sum of 2 quarters · filed 2024-11-07 | $20.91M derived: sum of 3 quarters · filed 2024-11-07 | $27.72M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-06-30 | $6.99M 10-Q · filed 2024-11-07 | $13.82M derived: sum of 2 quarters · filed 2024-11-07 | $20.63M derived: sum of 3 quarters · filed 2025-02-28 | $26.98M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-03-31 | $6.84M 10-Q · filed 2024-11-07 | $13.64M derived: sum of 2 quarters · filed 2025-02-28 | $20.00M derived: sum of 3 quarters · filed 2025-02-28 | $26.51M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2022-12-31 | $6.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $13.16M derived: sum of 2 quarters · filed 2025-02-28 | $19.67M derived: sum of 3 quarters · filed 2025-02-28 | $26.32M 10-K · filed 2025-02-28 | |
| 2022-09-30 | $6.36M 10-Q · filed 2023-11-02 | $12.86M derived: sum of 2 quarters · filed 2023-11-02 | $19.51M 10-Q · filed 2022-11-03 | $25.91M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $6.51M 10-Q · filed 2023-11-02 | $13.16M 10-Q · filed 2022-08-03 | $19.55M derived: sum of 3 quarters · filed 2024-02-27 | $25.67M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | $6.65M 10-Q · filed 2023-11-02 | $13.05M derived: sum of 2 quarters · filed 2024-02-27 | $19.16M derived: sum of 3 quarters · filed 2024-02-27 | $25.15M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $6.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $12.51M derived: sum of 2 quarters · filed 2024-02-27 | $18.50M derived: sum of 3 quarters · filed 2024-02-27 | $23.58M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $6.11M 10-Q · filed 2022-11-03 | $12.11M derived: sum of 2 quarters · filed 2022-11-03 | $17.18M 10-Q · filed 2022-11-03 | $20.92M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-06-30 | $5.99M 10-Q · filed 2022-08-03 | $11.07M 10-Q · filed 2022-08-03 | $14.81M derived: sum of 3 quarters · filed 2023-02-23 | $18.17M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-03-31 | $5.08M 10-Q · filed 2022-05-04 | $8.82M derived: sum of 2 quarters · filed 2023-02-23 | $12.18M derived: sum of 3 quarters · filed 2023-02-23 | $14.73M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2020-12-31 | $3.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $7.10M derived: sum of 2 quarters · filed 2023-02-23 | $9.65M derived: sum of 3 quarters · filed 2023-02-23 | $12.81M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $3.36M 10-Q · filed 2021-11-04 | $5.91M derived: sum of 2 quarters · filed 2021-11-04 | $9.06M 10-Q · filed 2021-11-04 | $11.50M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-06-30 | $2.55M 10-Q · filed 2021-08-05 | $5.71M 10-Q · filed 2021-08-05 | $8.14M derived: sum of 3 quarters · filed 2022-02-24 | $10.60M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-03-31 | $3.15M 10-Q · filed 2021-05-06 | $5.59M derived: sum of 2 quarters · filed 2022-02-24 | $8.04M derived: sum of 3 quarters · filed 2022-02-24 | $10.29M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2019-12-31 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $4.89M derived: sum of 2 quarters · filed 2022-02-24 | $7.14M derived: sum of 3 quarters · filed 2022-02-24 | $9.41M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $2.45M 10-Q · filed 2020-11-05 | $4.70M derived: sum of 2 quarters · filed 2020-11-05 | $6.97M 10-Q · filed 2020-11-05 | $8.69M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-06-30 | $2.25M 10-Q · filed 2020-08-06 | $4.52M 10-Q · filed 2020-08-06 | $6.23M derived: sum of 3 quarters · filed 2021-02-24 | $8.76M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-03-31 | $2.27M 10-Q · filed 2020-05-04 | $3.98M derived: sum of 2 quarters · filed 2021-02-24 | $6.51M derived: sum of 3 quarters · filed 2021-02-24 | $8.74M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2018-12-31 | $1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $4.24M derived: sum of 2 quarters · filed 2021-02-24 | $6.47M derived: sum of 3 quarters · filed 2021-02-24 | $8.65M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $2.52M 10-Q · filed 2019-11-05 | $4.76M derived: sum of 2 quarters · filed 2019-11-05 | $6.94M 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | $2.24M 10-Q · filed 2019-08-01 | $4.42M 10-Q · filed 2019-08-01 | |||
| 2018-03-31 | $2.18M 10-Q · filed 2019-05-07 | ||||
| 2017-12-31 | $4.54M 10-K · filed 2020-02-25 | ||||
| 2016-12-31 | $2.09M 10-K · filed 2018-03-12 | ||||
| 2015-12-31 | $2.26M 10-K · filed 2017-03-14 | ||||
| 2014-12-31 | $237.00K 10-K · filed 2016-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |